We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

151 hedge funds and large institutions have $1.49B invested in Revance Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 45 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $1.25B → $1.49B (+$239M)

13% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 45

4% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 27

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 153 → 151 (-2)

51% less call options, than puts

Call options by funds: $6.53M | Put options by funds: $13.2M

Holders
151
Holders Change
-2
Holders Change %
-1.31%
% of All Funds
2.67%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
28
Increased
51
Reduced
45
Closed
27
Calls
$6.53M
Puts
$13.2M
Net Calls
-$6.68M
Net Calls Change
-$2.96M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$73.8M
2
PAI
Palo Alto Investors
California
+$17.6M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$12M
4
UBS AM
UBS AM
Illinois
+$8.61M
5
JP Morgan Chase
JP Morgan Chase
New York
+$6.4M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$21.3M
2
DCM
Driehaus Capital Management
Illinois
-$9.24M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$7.63M
4
Citadel Advisors
Citadel Advisors
Florida
-$6.4M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$3.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$11.5M -$1.26M -48,490 -11%
UBS AM
27
UBS AM
Illinois
$10.6M +$8.61M +332,453 +787%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$10.1M +$1.16M +44,618 +14%
PPA
29
Parametric Portfolio Associates
Washington
$7.36M -$945K -36,497 -12%
DCM
30
Driehaus Capital Management
Illinois
$6.42M -$9.24M -356,898 -61%
RPAM
31
Rhenman & Partners Asset Management
Sweden
$6.24M – – –
TCM
32
Tekla Capital Management
Massachusetts
$6.06M +$3.31M +127,968 +149%
OCM
33
Osterweis Capital Management
California
$4.96M -$534K -20,635 -11%
Ameriprise
34
Ameriprise
Minnesota
$4.53M +$708K +27,349 +21%
Morgan Stanley
35
Morgan Stanley
New York
$4.31M +$1.63M +63,121 +71%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$4.08M +$3.05M +117,736 +447%
Millennium Management
37
Millennium Management
New York
$4.08M +$3.73M +144,005 New
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$3.89M -$176K -6,798 -5%
Swiss National Bank
39
Swiss National Bank
Switzerland
$3.8M +$461K +17,800 +15%
CS
40
Credit Suisse
Switzerland
$3.05M +$1.32M +51,109 +91%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$2.85M -$80.3K -3,100 -3%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$2.72M +$207K +8,008 +9%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$2.7M +$673 +26 +0%
SEI Investments
44
SEI Investments
Pennsylvania
$2.66M -$389K -15,021 -14%
ETCM
45
Evolutionary Tree Capital Management
Virginia
$2.53M +$2.31M +89,348 New
State of New Jersey Common Pension Fund D
46
State of New Jersey Common Pension Fund D
New Jersey
$2.35M +$54.2K +2,093 +3%
EIM
47
Essex Investment Management
Massachusetts
$2.17M -$604K -23,329 -23%
HighTower Advisors
48
HighTower Advisors
Illinois
$2.06M -$628K -24,234 -25%
Bank of America
49
Bank of America
North Carolina
$1.72M -$726K -28,021 -32%
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$1.71M +$435K +16,800 +36%
1
2
3 4 5

RVNC Hedge Fund Activity: Q4 2020 in Review

151 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2020, worth a combined $1.49B — up 19% from $1.25B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new RVNC positions and 27 closed out — a net gain of 1 holder — while 51 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $73.8M. The largest seller was Franklin Resources, cutting an estimated $21.3M.

  • 151 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2020, down from 153 in Q3 2020.
  • Funds reported $1.49B of Revance Therapeutics, Inc. stock for Q4 2020, up 19% quarter-over-quarter.
  • 28 funds opened new Revance Therapeutics, Inc. positions in Q4 2020 and 27 closed out, a net change of +1 holder.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2020 was Fidelity Investments, an estimated $73.8M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2020 was Franklin Resources, an estimated $21.3M sold.

Based on aggregated 13F filings for Q4 2020.